JO
NVIV

John Overdeck’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

John Overdeck’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,521
Closed -$49K – 3238
2022
Q3 		$49K Buy
+11,521
New +$63.1K ﹤0.01% 2320
2020
Q3 		– Sell
-631
Closed -$25K – 3778
2020
Q2 		$25K Buy
+631
New +$24.6K ﹤0.01% 2861
2018
Q4 		– Sell
-15
Closed -$23K – 3813
2018
Q3 		$23K Buy
+15
New +$22.1K ﹤0.01% 3112

Other funds holding NVIV

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

John Overdeck's NVIV Position: Q4 2022 in Review

John Overdeck sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q4 2022, closing a stake of 11,521 shares — an estimated $49K sold.

John Overdeck first reported a position in NVIV in Q3 2018 and held it in 3 quarters. The position peaked at $49K in Q3 2022. 18 funds tracked by Wall St. Rank hold NVIV as of Q4 2022.

  • John Overdeck reported no remaining InVivo Therapeutics Holdings Corp position as of Q4 2022 after selling out during the quarter.
  • John Overdeck sold 11,521 InVivo Therapeutics Holdings Corp shares in Q4 2022, an estimated $49K.
  • John Overdeck first reported a position in InVivo Therapeutics Holdings Corp in Q3 2018 and held it in 3 quarters.
  • John Overdeck's InVivo Therapeutics Holdings Corp position peaked at $49K in Q3 2022.
  • 18 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q4 2022.

Based on Two Sigma Investments's 13F filing for Q4 2022, filed 14 Feb 2023.